Author:
NV Vasilyeva1,2*, IV Vybornova1, SV Kovyrshin1, TS Bogomolova1,2, IA Bosak1, GA Chilina1, OV Shadrivova
Author address:
1Kashkin Research Institute of Medical Mycology, North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
2Department of Medical Microbiology, North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
3Department of Clinical Mycology, Allergy and Immunology, North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
Full conference title:
10th Advances Against Aspergillosis and Mucormycosis
Date: 2 February 2022
Abstract:
Purpose:
Aspergillosis is a severe fungal disease which attacks debilitated people including patients with SARS-CoV-2 infection. Resistance of Aspergillus fumigatus clinical isolates to azoles has been reported in Europe and the USA. The aim of this study was to investigate in vitro susceptibilities to itraconazole and voriconazole of Aspergillus spp. clinical isolates from patients in Saint Petersburg, Russia.
Methods:
A total of 107 Aspergillus spp. clinical isolates (including 27 from patients with SARS-CoV-2 infection) were studied: A. fumigatus – 54, A. flavus – 21, A. niger – 17, A. terreus – 9, A. ustus – 2, A. calidoustus – 2, A. sydowii – 1, Neosartoria fischeri – 1. All isolates are deposited into the Russian Collection of Pathogenic Fungi. Antifungal susceptibility testing was performed by the broth microdilution technique according to the EUCAST definitive document E.DEF 9.3.2.
Results:
Voriconazole MICs (mg/l) ranged between 0.06 and 16 against A. fumigatus, 0.125 and 0.25 against A. flavus, 0.125 and 1 against A. niger, 0.125 and 0.5 against A. terreus. MICs of this antifungal agent against A. ustus , A. calidoustus, A. sydowii and N. fischeri isolates were 4, 2, 0,125 and 0.25 mg/l correspondingly (Table 1). According to the EUCAST clinical breakpoints only one strain of A. fumigatus was resistant to voriconazole (2%). This strain was isolated from a patient with chronic pulmonary aspergillosis without SARS-CoV-2 infection.
Itraconazole MICs (mg/l) ranged between 0.015 and 8 against A. fumigatus, 0.03 and 0.5 against A. flavus, 0.06 and 2 against A. niger, 0.03 and 1 against A. terreus. MICs of this antifungal agent against A. ustus, A. calidoustus, A. sydowii and N. fischeri isolates were 8, 8, 0,03 and 0.06 mg/l correspondingly. According to the EUCAST clinical breakpoints only one strain of A. fumigatus was resistant to itraconazole (2%). This strain was also resistant to voriconazole.
| Aspergillus species | Antifungal agent | MIC (mg/l) | ||||||||||
| 0.015 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | ||
| A. fumigatus (54) | VOR | – | – | 4 | 20 | 19 | 7 | 3 | – | – | – | 1 |
| ITR | 1 | 3 | 14 | 15 | 4 | 10 | 6 | – | – | 1 | – | |
| A. flavus
(21) |
VOR | – | – | – | 15 | 5 | 1 | – | – | – | – | – |
| ITR | – | 6 | 8 | 5 | – | 2 | – | – | – | – | – | |
| A. niger
(17) |
VOR | – | – | – | 2 | 7 | 5 | 3 | – | – | – | – |
| ITR | – | – | 1 | 7 | 3 | 5 | – | 1 | – | – | – | |
| A. terreus
(9) |
VOR | – | – | – | 7 | 1 | 1 | – | – | – | – | – |
| ITR | – | 2 | 4 | 1 | 1 | – | 1 | – | – | – | – | |
| A.ustus
(2) |
VOR | – | – | – | – | – | – | – | – | 2 | – | – |
| ITR | – | – | – | – | – | – | – | – | – | 2 | – | |
| A. calidoustus
(2) |
VOR | – | – | – | – | – | – | – | 2 | – | – | – |
| ITR | – | – | – | – | – | – | – | – | – | 2 | – | |
| A. sydowii
(1) |
VOR | – | – | – | 1 | – | – | – | – | – | – | – |
| ITR | – | 1 | – | – | – | – | – | – | – | – | – | |
| Neosartoryafischeri
(1) |
VOR | – | – | – | – | 1 | – | – | – | – | – | – |
| ITR | – | – | 1 | – | – | – | – | – | – | – | – | |
Conclusion:
Resistance rates to voriconazole and itraconazole in clinical isolates of Aspergillus spp. in Saint Petersburg, Russia is low (2% in A. fumigatus for both antifungal agents).
Abstract Number: 61
Conference Year: 2022
Link to conference website: https://aaam2022.org/
URL Conference abstract: